Human preoptic regulatory factor-2 and uses thereof
OwnerXuan Mei Li, Paul Robert Rosteck +3inventors
InventorsXuan Mei Li, Paul Robert Rosteck, Eric Wen Su, He Wang, Jian-Jun Wei
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel hPORF-2 polypepiides, including isolated nucleic acids that encode hPORF-2 polypeptides, vectors, host cells, transgenics, chimerics, and hPORF-2-specific antibodies, as well as methods of making and using such.
Claims27
An isolated nucleic acid comprising at least one hPORF-2 polynucleotide encoding at least 90-100% of the contiguous amino acids of a protein sequence as shown in at least one of SEQ ID NOS:
- 5 or 6.
An isolated nucleic acid, comprising at least one hPORF-2 polynucleotide comprising or complementary to at least 90-100% of the contiguous nucleotides of at least one of SEQ ID NOS:
- 1, 2, 3, or 4.
An isolated polypeptide comprising an hPORF-2 polypeptide comprising at least 90-100% of the contiguous amino acids of at least one amino acid sequence of SEQ ID NOS:
- 5 or 6.
An isolated polypeptide comprising at least one polypeptide comprising at least 90-100% of the contiguous amino acids of at least one extracellular, intracellular, transmembrane or active domain of at least one of SEQ ID NOS:
- 5 or 6.
An isolated nucleic acid probe, fragment, or primer, comprising an hPORF-2 polynucleotide comprising a sequence corresponding or complementary to at least 10 nucleotides of any one of SEQ ID NOS:
- 1, 2, 3, or 4.
A method for identifying compounds that bind at least one hPORF-2 polypeptide, comprising
- (a) admixing at least one isolated hPORF-2 polypeptide with at least one test compound or composition;
- and
- (b) detecting at least one binding interaction between said at least one hPORF-2 polypeptide and the test compound or composition.
A method of identifying compounds capable of inhibiting hPORF-2 activity wherein said method comprises:
- a) administering an experimental compound to 1) an hPORF-2 transgenic non-human animal exhibiting one or more physiological, pathological, psychological, or behavioral conditions attributable to the overexpression of an hPORF-2 transgene or 2) tissues derived therefrom;
- and
- b) observing or assaying said animal and/or animal tissues to detect changes in said condition or conditions.
A method of identifying compounds capable of overcoming deficiencies in hPORF-2 activity wherein said method comprises the steps of:
- a) administering an experimental compound to 1) an hPORF-2 transgenic non-human animal exhibiting one or more physiological, pathological, psychological, or behavioral conditions attributable to the disruption of the endogenous PORF-2 gene;
- or 2) tissues derived therefrom;
- and
- b) observing or assaying said animal or animal tissues to detect changes in said condition or conditions.
A method of identifying a compound which can modulate the activity of the hPORF-2 protein wherein said method comprises the steps of:
- a) transfecting a mammalian host cell with an expression vector comprising DNA encoding an hPORF-2 protein;
- b) culturing said host cell under conditions such that the hPORF-2 protein is expressed;
- c) exposing said host cell so transfected to a test compound;
- and
- d) measuring a change in a physiological condition known to be influenced by the activity of the hPORF-2 protein relative to transfected host cells not exposed to said test compound.
The use of a polypeptide selected from the group consisting of:
- a) a polypeptide as shown in SEQ ID NO:
- 5;
- b) a polypeptide as shown in SEQ ID NO:
- 6;
- c) a polypeptide which is at least 90% identical to a polypeptide as in a) or b);
- d) any fragment of a polypeptide as in a), b), or c) for the manufacture of a medicament for the treatment or prevention of a disease in which aberrant levels of endogenous, PORF-2 polypeptide are at least partially responsible for inducing the cellular effects that lead to said disease.
The use of an antisense nucleic acid molecule which is complementary to at least 15 contiguous nucleotides of an mRNA molecule encoded by a polynucleotide selected from the group consisting of:
- a) a polynucleotide which has at least 90% identity to at least 40 contiguous nucleotides of at least one of SEQ ID NOS:
- 1, 2, 3, or 4;
- b) a polynucleotide which has at least 95% identity to at least 40 contiguous nucleotides of at least one of SEQ ID NOS:
- 1, 2, 3, or 4;
- and
- c) a polynucleotide as shown in at least one of SEQ ID NOS:
- 1, 2, 3, or 4;
- whereby said compound binds to said mRNA such that translation of said mRNA is inhibited for the manufacture of a medicament for the treatment or prevention of a disease in which aberrant levels of endogenous PORF-2 polypeptide are at least partially responsible for inducing the cellular effects that lead to said disease.
A pharmaceutical composition containing a polypeptide selected from the group consisting of:
- a) a polypeptide as shown in SEQ ID NO:
- 5;
- b) a polypeptide as shown in SEQ ID NO:
- 6;
- c) a polypeptide which is at least 90% identical to a polypeptide as in a) or b);
- and
- d) any fragment of a polypeptide as in a), b), or c) for treating or preventing a disease in which aberrant levels of endogenous PORF-2 polypeptide are at least partially responsible for inducing the cellular effects that lead to said disease.
A pharmaceutical composition containing an antisense nucleic acid molecule which is complementary to at least 15 contiguous nucleotides of an mRNA molecule encoded by a polynucleotide selected from the group consisting of:
- a) a polynucleotide which has at least 90% identity to at least 40 contiguous nucleotides of at least one of SEQ ID NOS:
- 1, 2, 3, or 4;
- b) a polynucleotide which has at least 95% identity to at least 40 contiguous nucleotides of at least one of SEQ ID NOS:
- 1, 2, 3, or 4;
- and
- c) a polynucleotide as shown in at least one of SEQ ID NOS:
- 1, 2, 3, or 4;
- whereby said compound binds to said mRNA such that translation of said mRNA is inhibited for the manufacture of a medicament for treating or preventing a disease in which aberrant levels of endogenous PORF-2 polypeptide are, at least partially, responsible for inducing the cellular effects that lead to said disease.
Dependencies are inferred from the claim text.